Pendulum Therapeutics is disrupting the probiotics industry. Pioneering the next frontier to restore metabolic health, the biotech company develops microbiome-targeted products that have the power and efficacy of a pharmaceutical with the safety and accessibility of a probiotic. Led by Colleen Cutcliffe, CEO and Co-founder who received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University, Pendulum was founded in 2012 by a diverse team of scientists with deep microbiology, biochemistry, computational and clinical expertise. In a published clinical trial, Pendulum’s flagship product, Pendulum Glucose Control, a medical probiotic, demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in individuals with T2D taking metformin.
Armed with 18 patents and 66 pending, Pendulum has raised $111 million to date from Sequoia Capital, Meritech CapitalTrue Ventures, Khosla Ventures, AME Cloud Ventures, and Mayo Clinic. Pendulum Therapeutics is headquartered in San Francisco.
Founding Story
Colleen Cutcliffe has an impressive background leading and managing biology teams. She’s a scientist with a Ph.D. in Biochemistry and Microbiology from Johns Hopkins University and has held senior positions at bioscience and pharmaceutical firms. She’s also a mom, not to mention our CEO.
Colleen and her two co-founders, John and Jim, saw an opportunity to apply next-generation DNA sequencing technologies and microbiological assays to the emerging microbiome science space. Using these data, they could create metabolic maps of the microbiome and use systems biology to make novel insights into the microbiome. This scientific trio was uniquely positioned to bring new products to the world.
You must be signed in as a media user to
and interact with hundreds of media-ready brands.
Create your Media account
×
Request Samples
Please fill out the following information:
×
Loading...
Contact Brand
Please fill out the following information:
×
Loading...
Features
Retailers
Pendulum products are available online at Amazon, Pendulum Therapeutics website, Dr. Mark Hyman Store, Walmart Marketplace, Fullscript and The Cleveland Clinic online pharmacy.
Colleen Cutcliffe is the Chief Executive Officer and co-founder of Pendulum. Colleen has more than 25 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology.
Prior to co-founding Pendulum, Colleen was the senior manager of biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals. Colleen completed her postdoctoral studies at Northwestern’s Children’s Memorial Hospital. Colleen received her PhD in Biochemistry and Molecular Biology from John Hopkins University and her BA in Biochemistry from Wellesley College.
Jennifer McManus is a registered dietitian (RD) and certified diabetes care and education specialist (CDCES) at Pendulum Therapeutics. Jen obtained her undergraduate degree in Dietetics from Florida State University. Upon graduation, she went on to complete her dietetic internship at Vanderbilt University Medical Center. She started her career in the clinical setting covering numerous disease states including cardiovascular disease, diabetes and acutely-ill patients. Jennifer has a passion for educating on the power of the microbiome.
John Eid is the Chief Science Officer and co-founder of Pendulum. John has led technology development teams for over two decades in diverse areas that include advanced microscopy, single molecule detection and analyses, automated data acquisition systems, biophysical systems modeling, and genome sequencing applications.
Prior to co-founding Pendulum, John was a principal scientist at Pacific Biosciences. John completed his postdoctoral research at the Roland Institute at Harvard University, received his PhD in Biophysics and Computational Biology at the University of Illinois, Urbana Champaign and his BS in Applied and Engineering Physics from Cornell University.
